Stoneprime US

The principal activity of Stoneprime US is investing in the biotechnology sector, combining finance, biotechnology and artificial intelligence. The company develops qualitative and quantitative AI algorithms to automate scientific analysis and assess the development potential of publicly traded biotech companies in the United States.

Stoneprime US offers investment solutions based on predictive analysis of FDA approval for new drugs, using AI to anticipate market reactions to scientific discoveries. The products and services are primarily aimed at institutional investors, high-net-worth individuals, family offices and venture capital funds wishing to invest in the biotech sector with an innovative, AI-based approach.

Stoneprime US is an innovative company at the intersection of finance, biotechnology, and artificial intelligence. Here are the major milestones in its history and development:

Founding and mission:
Stoneprime US was founded with the goal of revolutionizing investment in the biotech sector through artificial intelligence. The company develops qualitative and quantitative AI algorithms to automate scientific analysis and assess the development potential of biotech companies listed on the US market.

Products and innovations:
Stoneprime US offers patented solutions (provisional patent no. 63/634,059, technology patent pending) based on two main pillars:

• Qualitative AI: analysis of resources, skills, and CVs of the management teams of target companies, as well as the quality of their research (molecules, competitors, publications, scientific citations, etc.).
• Quantitative AI: identification of ideal entry points on stocks, detection of micro-market movements, and multi-perspective asset analysis to reveal signals invisible to the human eye.

Strategy and positioning:
Stoneprime US adopts a unique investment strategy focused on anticipating market reactions to potential FDA drug approvals. The company targets more than 500 companies in the biotech sector, combining the power of AI with a rigorous scientific approach.

Partnerships and investors:
Stoneprime US serves a diverse clientele: institutional investors, high-net-worth individuals, family offices, and venture capital funds, offering them an innovative and precise investment experience.

Strategic changes and outlook:
The company continues to develop its proprietary technologies and further refines its algorithms to remain at the forefront of AI-driven biotech analysis. It positions itself as a pioneer in AI-driven biotech investment, with particular attention paid to protecting its innovations through patent filings.

For more information, visit the official website: stoneprime.us

Founder and Key Members of the Stoneprime US Executive Team

Founders:
- Antonio Simeone – Co-founder & CEO
- Giorgio Casaburi – Co-founder & Head of Scientific Committee
- Emanuele Ricco – Co-founder & Quantitative Researcher

Key Members of the Executive Team:
- Claudio Bruni – Strategist

Advisory Board:
- Gabriele Grego – Founder Quintessential Capital
- James Hodson – CEO AI for Good Foundation
- Simona Tiribelli – Director for AI Ethics, Institute for Technology & Global Health

Scientific Committee:
- Roberto Maiolino – Professor of Experimental Astrophysics, University of Cambridge
- Giuseppe F. Italiano – Professor of Computer Science, LUISS Guido Carli University
- Adriana Chiarelli – PhD in Microbiology
- Maddalena Pacelli – PhD Candidate in Immunotherapy
- Geoffrey Stephens – Founder & CEO Aicella

For more details, see the official team page on stoneprime.us.